|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
IGA Glomerulonephritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy.
|
28672768 |
2017 |
|
IGA Glomerulonephritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
In patients, however, CD89/IgA complexes were detected, and injection of patient IgA induced IgAN-like features in CD89 Tg mice.
|
27437939 |
2016 |
|
IGA Glomerulonephritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
This result does, however, not preclude the implication of other CD89 polymorphisms neither the possibility for a role of CD89 in the pathogenesis of IgA nephropathy.
|
21750160 |
2012 |
|
IGA Glomerulonephritis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Our results provide evidence for genetic variation at the putative promoter region of FCAR conferring susceptibility to IgAN, suggesting -27C and its haplotype may be causative for the susceptibility among the Chinese Han population.
|
21273231 |
2011 |
|
IGA Glomerulonephritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Understanding how IgA triggers shedding of CD89 from myeloid cell surfaces could help clarify the process of immune complex formation in IgAN, and measurement of this soluble form of CD89 may in the future prove a useful prognostic indicator of end-stage renal disease in this common glomerulonephritis.
|
21116273 |
2010 |
|
IGA Glomerulonephritis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
However, no association between CD89 gene polymorphisms and susceptibility to IgAN was detected.
|
20811333 |
2010 |
|
IGA Glomerulonephritis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms in the promoter and 5' UTR region of the Fc alpha receptor (CD89) are not associated with a risk of IgA nephropathy.
|
11776381 |
2001 |
|
IGA Glomerulonephritis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice.
|
10839814 |
2000 |
|
IGA Glomerulonephritis
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
IgA nephropathy-specific expression of the IgA Fc receptors (CD89) on blood phagocytic cells.
|
9367406 |
1997 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In this transgenic mouse model, the CD89 bispecific antibody showed significant anti-tumor activities, demonstrating that bispecific antibodies can redirect macrophages, including M2 macrophages, to mediate additional effector function in the tumor microenvironment.
|
29296544 |
2017 |
|
Glomerulonephritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
No deposition of IgA-CD89 complexes or glomerulonephritis was detected, however.
|
27437939 |
2016 |
|
Glomerulonephritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Understanding how IgA triggers shedding of CD89 from myeloid cell surfaces could help clarify the process of immune complex formation in IgAN, and measurement of this soluble form of CD89 may in the future prove a useful prognostic indicator of end-stage renal disease in this common glomerulonephritis.
|
21116273 |
2010 |
|
Glomerulonephritis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Fc alpha receptor I activation induces leukocyte recruitment and promotes aggravation of glomerulonephritis through the FcR gamma adaptor.
|
17393381 |
2007 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Anti-FcalphaRI Fab treatment of nude mice injected subcutaneously with FcalphaRI+ mast-cell transfectants prevented tumor development and halted the growth of established tumors.
|
16990604 |
2007 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Previous studies have demonstrated that, in addition to IgG Fc receptors, the human myeloid IgA receptor (Fc(alpha)RI, CD89) also effectively triggered tumor cell killing.
|
12393717 |
2002 |
|
Septicemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
In vivo, CD89 transgenic mice are protected in two different models of sepsis: a model of pneumonia and the cecal ligation and puncture (CLP) polymicrobial model of infection.
|
30995475 |
2019 |
|
Sepsis
|
0.020 |
Biomarker
|
disease |
BEFREE |
In vivo, CD89 transgenic mice are protected in two different models of sepsis: a model of pneumonia and the cecal ligation and puncture (CLP) polymicrobial model of infection.
|
30995475 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, as IgA induces neutrophil recruitment, novel therapeutic strategies that aim to target the IgA Fc receptor FcαRI may fully unleash the potential of enlisting neutrophils as cytotoxic effector cells in antibody therapy of cancer.
|
29855035 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
However, as IgA induces neutrophil recruitment, novel therapeutic strategies that aim to target the IgA Fc receptor FcαRI may fully unleash the potential of enlisting neutrophils as cytotoxic effector cells in antibody therapy of cancer.
|
29855035 |
2018 |
|
Septicemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this review, we summarize the molecular and functional characteristics of Fcα/μR in comparison with poly-IgR, FcμR and FcαRI, and focus particularly on the pro-inflammatory function of Fcα/μR expressed on marginal zone B cells in sepsis.
|
29281010 |
2017 |
|
Sepsis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this review, we summarize the molecular and functional characteristics of Fcα/μR in comparison with poly-IgR, FcμR and FcαRI, and focus particularly on the pro-inflammatory function of Fcα/μR expressed on marginal zone B cells in sepsis.
|
29281010 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
This process also opens up the possibility of targeting FcαRI in antibody immunotherapy of cancer.
|
26497517 |
2015 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
This process also opens up the possibility of targeting FcαRI in antibody immunotherapy of cancer.
|
26497517 |
2015 |
|
Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In vivo, CD89 transgenic mice are protected in two different models of sepsis: a model of pneumonia and the cecal ligation and puncture (CLP) polymicrobial model of infection.
|
30995475 |
2019 |